Study Stopped
devices applied in the study were no more available in the market, and medical intervention section was completed.
Shanghai Registry of Acute Coronary Events
Phase 4 Study to Compare Different Therapeutic Strategies for Patients With ACS
1 other identifier
observational
20,000
1 country
1
Brief Summary
SRACE is an multicenter observational database of outcomes for patients who are hospitalized with an acute coronary events. SRACE includes over 20 hospitals in Shanghai China that have enrolled a total of more than 3,000 patients since 2005, with an annual enrollment of 500 patients. The major purpose of the SRACE program is to evaluate the prognosis of patients admitted to the hospital due to acute coronary events, comparing different therapeutic strategies, in-hospital transferring system, and so on. All participating physicians receive confidential quarterly reports showing ther outcomes side-by-side with the aggregate outcomes of all participating hospitals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2005
CompletedFirst Submitted
Initial submission to the registry
July 7, 2008
CompletedFirst Posted
Study publicly available on registry
July 11, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2018
CompletedOctober 13, 2016
October 1, 2016
12.8 years
July 7, 2008
October 12, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
major adverse cardiac events(MACE), including death, non-fatal re-MI, and target vessel revascularization
in-hospital, 30d, and long-term follow-up
Secondary Outcomes (1)
stroke, stent thrombosis
in-hospital, 30d, and long-term follow-up
Study Arms (6)
1
patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy
2
patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI
3
patients with non-ST-elevation ACS treated by immediate PCI
4
patients with non ST-elevation ACS treated by elective PCI
5
STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.
6
STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).
Interventions
drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
Eligibility Criteria
patients admitted to the hospital with acute coronary syndrome
You may qualify if:
- patients admitted to the hospital with acute coronary syndrome and received medical or interventional treatment
You may not qualify if:
- non ACS patients;
- complicated with other lethal disease
- predicted life span less than 12 months
- known allergy history to any anti-platelet or anti-thrombin medicine
- unconscious at the time of arrival at the hospital
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dept. of Cardiology, Ruijin Hospital
Shanghai, Shanghai Municipality, 200025, China
Related Publications (4)
Zhang Q, Zhang RY, Qiu JP, Zhang JF, Wang XL, Jiang L, Liao ML, Zhang JS, Hu J, Yang ZK, Shen WF. Prospective multicenter randomized trial comparing physician versus patient transfer for primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction. Chin Med J (Engl). 2008 Mar 20;121(6):485-91.
PMID: 18364130RESULTZhang Q, Zhang RY, Qiu JP, Zhang JF, Wang XL, Jiang L, Liao ML, Zhang JS, Hu J, Yang ZK, Shen WF. One-year clinical outcome of interventionalist- versus patient-transfer strategies for primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results from the REVERSE-STEMI study. Circ Cardiovasc Qual Outcomes. 2011 May;4(3):355-62. doi: 10.1161/CIRCOUTCOMES.110.958785. Epub 2011 Apr 26.
PMID: 21521833RESULTQiu JP, Zhang Q, Lu JD, Wang HR, Lin J, Ge ZR, Zhang RY, Shen WF. Direct ambulance transport to catheterization laboratory reduces door-to-balloon time in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the DIRECT-STEMI study. Chin Med J (Engl). 2011 Mar;124(6):805-10.
PMID: 21518584RESULTZhang Q, Qiu JP, Kirtane AJ, Zhu TQ, Zhang RY, Yang ZK, Hu J, Ding FH, DU R, Shen WF. Comparison of biodegradable polymer versus durable polymer sirolimus-eluting stenting in patients with acute st-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the RESOLVE study. J Interv Cardiol. 2014 Apr;27(2):131-41. doi: 10.1111/joic.12102.
PMID: 24697948DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wei Feng Shen, MD,PhD
Ruijin Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
July 7, 2008
First Posted
July 11, 2008
Study Start
March 1, 2005
Primary Completion
January 1, 2018
Last Updated
October 13, 2016
Record last verified: 2016-10